Sugi Predict

Sugi Predict / Compounds / SCHEMBL2265404

SCHEMBL2265404

SCHEMBL2265404

O=C1C=C(c2cnc3cccnn23)C(=O)N1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.50
▸ KLK7 P49862 1/20 0.43
▸ DYRK1A Q13627 2/20 0.43
▸ PRMT5 O14744 1/20 0.41
▸ WDR77 Q9BQA1 1/20 0.41
▸ GSK3A P49840 2/20 0.41
▸ GSK3B P49841 2/20 0.41
▸ LRRK2 Q5S007 1/20 0.37
▸ MAP4K1 Q92918 1/20 0.37
▸ KDR P35968 2/20 0.36
▸ CDK1 P06493 1/20 0.35
▸ SSTR4 P31391 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ FYN P06241 1/20 0.33
▸ MARK3 P27448 2/20 0.32
▸ ABL1 P00519 2/20 0.32
▸ BCR P11274 2/20 0.32
▸ CDK2 P24941 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263881 0.75 FLT3 (0.47) DYRK1APRMT5WDR77GSK3AGSK3B
Hydrochloric Acid SCHEMBL4032782 0.74 FLT3 (0.46) DYRK1APRMT5WDR77GSK3AGSK3B
SCHEMBL2261834 0.70 CDK8 (0.50) DYRK1AMAP4K1KDR
SCHEMBL2261411 0.70 PRMT5 (0.40) PRMT5WDR77GSK3AGSK3BMAP4K1
SCHEMBL22189861 0.68 MKNK1 (0.77) MKNK1KLK7DYRK1APRMT5WDR77
SCHEMBL4041609 0.68 PRMT5 (0.42) PRMT5WDR77
SCHEMBL3832037 0.68 CYP1A2 (0.43) PRMT5WDR77GSK3B
SCHEMBL1744648 0.67 MKNK1 (1.00) MKNK1KLK7DYRK1AFYN
SCHEMBL4036874 0.67 PRMT5 (0.44) PRMT5WDR77KDR
SCHEMBL2265649 0.67 BACE1 (0.49) DYRK1AGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-12-01 — — US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 — — US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 — — US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 — — US disclosed
US-7491716-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2009-02-17 — — US disclosed
US-20050090483-A1 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY 2005-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090483-A1 Purine derivatives as kinase inhibitors PNP, ADK, NME2 MKNK1 312/4885KLK7 3312/4885DYRK1A 1130/4885
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 MKNK1 312/4885KLK7 3312/4885DYRK1A 1130/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 MKNK1 312/4885KLK7 3312/4885DYRK1A 1130/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 MKNK1 312/4885KLK7 3312/4885DYRK1A 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.